PPCM
MCID: PRP009
MIFTS: 55

Peripartum Cardiomyopathy (PPCM)

Categories: Blood diseases, Cardiovascular diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Peripartum Cardiomyopathy

MalaCards integrated aliases for Peripartum Cardiomyopathy:

Name: Peripartum Cardiomyopathy 56 12 74 52 58 15 17 71
Postpartum Cardiomyopathy 52 58 71
Peripartum Cardiomyopathy, Susceptibility to 56
Antepartum Peripartum Cardiomyopathy 12
Postpartum Peripartum Cardiomyopathy 12
Cardiomyopathy, Peripartum 39
Ppcm, Susceptibility to 56
Meadows' Syndrome 52
Ppcm 56

Characteristics:

Orphanet epidemiological data:

58
peripartum cardiomyopathy
Age of onset: Adult;

Classifications:

Orphanet: 58  
Rare gynaecological and obstetric diseases


Summaries for Peripartum Cardiomyopathy

OMIM : 56 Peripartum cardiomyopathy (PPCM) is characterized by systolic heart failure presenting in the last month of pregnancy or the first 5 months postpartum. PPCM affects 1 in 300 to 1 in 3,000 pregnancies, with geographic hot spots of high incidence, such as Nigeria and Haiti. Although approximately half of affected women recover cardiac function postpartum, many patients progress to chronic heart failure, cardiac transplantation, or death. Data have suggested that antiangiogenic prolactin (176760) fragments may have an important role in causing the disease in some patients. Risk factors for PPCM also include preeclampsia (see 189800) and multiple gestation, suggesting a potential mechanistic overlap with these processes (summary by Patten et al., 2012). (614670)

MalaCards based summary : Peripartum Cardiomyopathy, also known as postpartum cardiomyopathy, is related to atrial standstill 1 and systolic heart failure. An important gene associated with Peripartum Cardiomyopathy is MIR146A (MicroRNA 146a), and among its related pathways/superpathways are G-Beta Gamma Signaling and PI3K-Akt signaling pathway. The drugs Selenium and Selenious acid have been mentioned in the context of this disorder. Affiliated tissues include heart, thyroid and testes, and related phenotypes are fatigue and congestive heart failure

NIH Rare Diseases : 52 The following summary is from Orphanet , a European reference portal for information on rare diseases and orphan drugs. Orpha Number: 563 Definition Peripartum cardiomyopathy (PPCM) is an idiopathic, potentially fatal form of dilated cardiomyopathy that develops during the final month of pregnancy or within five months after delivery. Visit the Orphanet disease page for more resources.

Wikipedia : 74 Peripartum cardiomyopathy (PPCM) is a form of dilated cardiomyopathy that is defined as a deterioration... more...

Related Diseases for Peripartum Cardiomyopathy

Diseases related to Peripartum Cardiomyopathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 292)
# Related Disease Score Top Affiliating Genes
1 atrial standstill 1 31.9 TTN SCN5A MYH7 ADRB1 ACE
2 systolic heart failure 31.2 TTN ADRB1 ACE
3 eclampsia 31.1 VEGFA PGF FLT1 ACE
4 cardiac arrest 31.0 TTN SCN5A MYH7 ACE
5 congestive heart failure 30.7 VEGFA TTN SCN5A MYH7 ADRB1 ACE
6 pre-eclampsia 30.7 VEGFA PGF MIR210 FLT1 ACE
7 dilated cardiomyopathy 30.4 VEGFA TTN SCN5A PDCD1 MYH7 MIR146A
8 ectopic pregnancy 30.1 VEGFA PGF FLT1
9 atrioventricular block 30.0 TTN SCN5A MYH7 ACE
10 hellp syndrome 30.0 VEGFA PGF FLT1
11 retinal artery occlusion 30.0 VEGFA PGF FLT1 ACE
12 placenta disease 30.0 VEGFA PGF MIR146A FLT1
13 long qt syndrome 29.9 TTN SCN5A MYH7 ADRB1
14 ischemia 29.8 VEGFA MIR21 MIR195 ACE
15 peripheral nervous system disease 29.4 VEGFA MIR21 MIR146A ACE
16 limb ischemia 28.9 VEGFA PGF MIR210 MIR21 ACE
17 heart disease 27.8 VEGFA TTN SCN5A PGF MYH7 MIR210
18 systemic lupus erythematosus 27.6 VEGFA PRL PDCD1 MIR210 MIR21 MIR195
19 leukemia, acute myeloid 27.6 VEGFA NRAS MIR210 MIR21 MIR195 MIR146A
20 myocardial infarction 27.3 VEGFA SCN5A PGF MYH7 MIR210 MIR21
21 body mass index quantitative trait locus 11 27.1 VEGFA PRL MIR21 MIR146A MIR10A GNB3
22 myocarditis 10.7
23 cardiogenic shock 10.6
24 pulmonary edema 10.6
25 pulmonary embolism 10.5
26 microcystic meningioma 10.4 VEGFA FLT1
27 cardiac conduction defect 10.4
28 galactorrhea 10.4 PRL DRD2
29 glomeruloid hemangioma 10.4 VEGFA PRL FLT1
30 hypertensive encephalopathy 10.3 VEGFA FLT1 ACE
31 lipodermatosclerosis 10.3 VEGFA FLT1
32 acute mountain sickness 10.3 VEGFA FLT1 ACE
33 prolactin producing pituitary tumor 10.3 PRL DRD2
34 uterine benign neoplasm 10.3 VEGFA PRL MIR146A
35 third-degree atrioventricular block 10.3 TTN SCN5A ACE
36 progressive familial heart block, type ia 10.3
37 left ventricular noncompaction 10.3
38 cardiomyopathy, dilated, 1b 10.3 TTN SCN5A MYH7
39 cancer-associated retinopathy 10.3 VEGFA PGF FLT1
40 epithelioid hemangioendothelioma 10.3 VEGFA PGF FLT1
41 first-degree atrioventricular block 10.3 SCN5A MYH7 ACE
42 familial isolated dilated cardiomyopathy 10.3 TTN SCN5A MYH7
43 autoimmune disease 10.3
44 ventricular fibrillation, paroxysmal familial, 1 10.3
45 respiratory failure 10.3
46 kuhnt-junius degeneration 10.3 VEGFA PGF FLT1
47 neovascular glaucoma 10.3 VEGFA PGF FLT1
48 blood group, globoside system 10.3 VEGFA PGF FLT1
49 retinal vascular occlusion 10.3 VEGFA PGF FLT1
50 severe nonproliferative diabetic retinopathy 10.3 VEGFA PGF ACE

Graphical network of the top 20 diseases related to Peripartum Cardiomyopathy:



Diseases related to Peripartum Cardiomyopathy

Symptoms & Phenotypes for Peripartum Cardiomyopathy

Human phenotypes related to Peripartum Cardiomyopathy:

58 31 (show all 45)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 fatigue 58 31 frequent (33%) Frequent (79-30%) HP:0012378
2 congestive heart failure 58 31 frequent (33%) Frequent (79-30%) HP:0001635
3 hypertension 58 31 frequent (33%) Frequent (79-30%) HP:0000822
4 dilated cardiomyopathy 58 31 frequent (33%) Frequent (79-30%) HP:0001644
5 left ventricular hypertrophy 58 31 frequent (33%) Frequent (79-30%) HP:0001712
6 pedal edema 58 31 frequent (33%) Frequent (79-30%) HP:0010741
7 reduced ejection fraction 58 31 frequent (33%) Frequent (79-30%) HP:0012664
8 exertional dyspnea 58 31 frequent (33%) Frequent (79-30%) HP:0002875
9 sinus tachycardia 58 31 frequent (33%) Frequent (79-30%) HP:0011703
10 abnormal t-wave 58 31 frequent (33%) Frequent (79-30%) HP:0005135
11 palpitations 58 31 frequent (33%) Frequent (79-30%) HP:0001962
12 elevated jugular venous pressure 58 31 frequent (33%) Frequent (79-30%) HP:0030848
13 orthopnea 58 31 frequent (33%) Frequent (79-30%) HP:0012764
14 pulmonary arterial hypertension 58 31 occasional (7.5%) Occasional (29-5%) HP:0002092
15 chest pain 58 31 occasional (7.5%) Occasional (29-5%) HP:0100749
16 mitral regurgitation 58 31 occasional (7.5%) Occasional (29-5%) HP:0001653
17 myocarditis 58 31 occasional (7.5%) Occasional (29-5%) HP:0012819
18 increased serum interferon-gamma level 58 31 occasional (7.5%) Occasional (29-5%) HP:0030356
19 preeclampsia 58 31 occasional (7.5%) Occasional (29-5%) HP:0100602
20 peripheral edema 58 31 occasional (7.5%) Occasional (29-5%) HP:0012398
21 ventricular tachycardia 58 31 occasional (7.5%) Occasional (29-5%) HP:0004756
22 thromboembolism 58 31 occasional (7.5%) Occasional (29-5%) HP:0001907
23 paroxysmal dyspnea 58 31 occasional (7.5%) Occasional (29-5%) HP:0012763
24 heart murmur 58 31 occasional (7.5%) Occasional (29-5%) HP:0030148
25 crackles 58 31 occasional (7.5%) Occasional (29-5%) HP:0030830
26 right ventricular failure 58 31 occasional (7.5%) Occasional (29-5%) HP:0001708
27 right ventricular dilatation 58 31 occasional (7.5%) Occasional (29-5%) HP:0005133
28 abnormal atrioventricular valve morphology 58 31 occasional (7.5%) Occasional (29-5%) HP:0006705
29 left atrial enlargement 58 31 occasional (7.5%) Occasional (29-5%) HP:0031295
30 anemia 58 31 very rare (1%) Very rare (<4-1%) HP:0001903
31 abdominal pain 58 31 very rare (1%) Very rare (<4-1%) HP:0002027
32 autoimmunity 58 31 very rare (1%) Very rare (<4-1%) HP:0002960
33 obesity 58 31 very rare (1%) Very rare (<4-1%) HP:0001513
34 diabetes mellitus 58 31 very rare (1%) Very rare (<4-1%) HP:0000819
35 asthma 58 31 very rare (1%) Very rare (<4-1%) HP:0002099
36 respiratory failure 58 31 very rare (1%) Very rare (<4-1%) HP:0002878
37 abnormality of thyroid physiology 58 31 very rare (1%) Very rare (<4-1%) HP:0002926
38 stroke-like episode 58 31 very rare (1%) Very rare (<4-1%) HP:0002401
39 cardiogenic shock 58 31 very rare (1%) Very rare (<4-1%) HP:0030149
40 left bundle branch block 58 31 very rare (1%) Very rare (<4-1%) HP:0011713
41 dyspnea 58 Frequent (79-30%)
42 tachycardia 58 Frequent (79-30%)
43 abnormal cardiac atrium morphology 58 Occasional (29-5%)
44 left ventricular systolic dysfunction 58 Frequent (79-30%)
45 toxemia of pregnancy 58 Occasional (29-5%)

Clinical features from OMIM:

614670

MGI Mouse Phenotypes related to Peripartum Cardiomyopathy:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.06 ACE ADRB1 DRD2 FLT1 MYH7 NRAS
2 homeostasis/metabolism MP:0005376 10.03 ACE ADRB1 CD274 DRD2 FLT1 MYH7
3 liver/biliary system MP:0005370 9.7 ACE DRD2 NRAS PDCD1 PRL SCN5A
4 muscle MP:0005369 9.56 ADRB1 DRD2 FLT1 MYH7 PDCD1 SCN5A
5 neoplasm MP:0002006 9.17 ACE DRD2 NRAS PDCD1 PGF PRL

Drugs & Therapeutics for Peripartum Cardiomyopathy

Drugs for Peripartum Cardiomyopathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 33)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Selenium Approved, Investigational, Vet_approved Phase 4 7782-49-2
2
Selenious acid Approved, Investigational Phase 4 7783-00-8
3 Trace Elements Phase 4
4 Antioxidants Phase 4
5 Sodium Selenite Phase 4
6 Nutrients Phase 4
7 Protective Agents Phase 4
8 Micronutrients Phase 4
9
Hydralazine Approved Phase 3 86-54-4 3637
10
Nitric Oxide Approved Phase 3 10102-43-9 145068
11
AT-101 Approved, Investigational Phase 3 652-67-5, 90141-22-3 12597
12
Isosorbide Dinitrate Approved, Investigational Phase 3 87-33-2 6883
13
Ethanol Approved Phase 3 64-17-5 702
14
Heparin Approved, Investigational Phase 3 9005-49-6 46507594 772
15
Dalteparin Approved Phase 3 9005-49-6
16
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
17
Tinzaparin Approved Phase 3 9041-08-1, 9005-49-6 25244225
18
Bromocriptine Approved, Investigational Phase 3 25614-03-3 31101
19
Taurine Approved, Nutraceutical Phase 2, Phase 3 107-35-7 1123
20 Antihypertensive Agents Phase 3
21 Vasodilator Agents Phase 3
22 diuretics Phase 3
23 isosorbide-5-mononitrate Phase 3
24 Pharmaceutical Solutions Phase 2, Phase 3
25 Dopamine Agents Phase 3
26 Dopamine agonists Phase 3
27 Hormone Antagonists Phase 3
28 Hormones Phase 3
29 Heparin, Low-Molecular-Weight Phase 3
30 Antiparkinson Agents Phase 3
31 Neurotransmitter Agents Phase 3
32 calcium heparin Phase 3
33 Angiotensin-Converting Enzyme Inhibitors Phase 2

Interventional clinical trials:

(show all 15)
# Name Status NCT ID Phase Drugs
1 Peripartum Cardiomyopathy in Nigeria (PEACE) A Registry to Study the Demographics, Social and Clinical Characteristics, Pathophysiology and Outcomes of Peripartum Cardiomyopathy in Nigeria Active, not recruiting NCT03081949 Phase 4 Oral Sodium Selenite 200 µg/day for 3 months
2 A Prospective, Placebo-controlled, Double-blind, Randomized Study to Compare Hydralazine-isosorbide-dinitrate(HYIS) Versus Placebo on Top of Std Care in African Patients With Acute Heart Failure (AHF) and Left Ventricular Dysfunction Unknown status NCT01822808 Phase 3 Hydralazine;Isosorbide Dinitrate
3 Impact of Continues Positive Airway Pressure Treatment in Patients With Dilated Cardiomyopathy and Obstructive Sleep Apnea (RIDA) Unknown status NCT02989181 Phase 3
4 Taurine for Early Left Ventricular Recovery in Peripartum Cardiomyopathy Completed NCT03907267 Phase 2, Phase 3 Taurine Solution
5 A Collaborative Model to Improve BP Control and Minimize Racial Disparities-CCC Completed NCT00935077 Phase 3
6 Bromocriptine in the Treatment of Peripartum Cardiomyopathy, A Bayesian Randomized Registry Trial Recruiting NCT02590601 Phase 3 Bromocriptine
7 Effect of Bromocriptine on LV Function in Women With Peripartum Cardiomyopathy A Randomized, Controlled Clinical Trial to Evaluate the Efficacy and Safety of Bromocriptine for Improvement of Left Ventricular Function of Women With PPCM Completed NCT00998556 Phase 2 Bromocriptine
8 Clinical A Nation-wide Registry of Peripartum Cardiomyopathy: Clinical Status in Turkey Unknown status NCT03364140
9 Pregnancy Related Cardiomyopathy Enrollment and Lessons in Web-Based Recruitment (PRiCELESS) Unknown status NCT00273637
10 Sub-project: Use of Small Implantable ECG Recorder in Pregnant Women With Arrhythmia Unknown status NCT02249195
11 Immune Activation and Myocardial Recovery in Peripartum Cardiomyopathy Completed NCT01085955
12 Preformed Pediatric Crown Zirconia Versus Preformed Pediatric Metal Crown PPC Z-M Recruiting NCT03296709
13 A Pharmacist Intervention for Monitoring and Treating Hypertension Using Bidirectional Texting Recruiting NCT03986931
14 Diastolic Dysfunction PPCM in Patients With Documented Left Ventricular Systolic Function Recovery Enrolling by invitation NCT04143997
15 Observational Study for Outcomes for Participants With Cardiogenic Shock and Peripartum Cardiomyopathy Not yet recruiting NCT04234659

Search NIH Clinical Center for Peripartum Cardiomyopathy

Genetic Tests for Peripartum Cardiomyopathy

Anatomical Context for Peripartum Cardiomyopathy

MalaCards organs/tissues related to Peripartum Cardiomyopathy:

40
Heart, Thyroid, Testes, Placenta, Monocytes, Bone Marrow, Bone

Publications for Peripartum Cardiomyopathy

Articles related to Peripartum Cardiomyopathy:

(show top 50) (show all 1255)
# Title Authors PMID Year
1
Cardiac angiogenic imbalance leads to peripartum cardiomyopathy. 61 56
22596155 2012
2
Extracorporeal membrane oxygenation in peripartum cardiomyopathy: A review of the ELSO Registry. 61
32321653 2020
3
T-Peak to T-End Improvements After Beta-Blocker Administration in Peripartum Cardiomyopathy Patients. 61
32494328 2020
4
Point-of-care ultrasound in pregnancy: gastric, airway, neuraxial, cardiorespiratory. 61
32324656 2020
5
Inhibition of the Notch1 pathway induces peripartum cardiomyopathy. 61
32529705 2020
6
Racial disparities in peripartum cardiomyopathy: eighteen years of observations. 61
32508175 2020
7
Pre-pregnancy Obesity and the Risk of Peripartum Cardiomyopathy. 61
32512606 2020
8
Common genetic predisposition for heart failure and cancer. 61
32542459 2020
9
β1 adrenoceptor antibodies induce myocardial apoptosis via inhibiting PGC-1α-related pathway. 61
32503464 2020
10
Mode of delivery is an independent risk factor for maternal mortality: a case-control study. 61
32498579 2020
11
Clinical features differentiating Takotsubo cardiomyopathy in the peripartum period from peripartum cardiomyopathy. 61
31705186 2020
12
Dilated cardiomyopathies and non-compaction cardiomyopathy. 61
32107565 2020
13
Matrix Metalloproteases and Cathepsin D in Human Serum do not Cleave Prolactin to Generate Vasoinhibin. 61
32390374 2020
14
The European Society of Cardiology Heart Failure Association Study Group on Peripartum Cardiomyopathy - what has been achieved in 10 years. 61
32452103 2020
15
Peripartum cardiomyopathy: can the link between prolactin and PAI-1 provide a clue? 61
32395751 2020
16
Post-Traumatic Stress, Depression, and Quality of Life in Women with Peripartum Cardiomyopathy. 61
32341249 2020
17
Fragmented QRS as a candidate marker for left ventricular nonrecovery in patients with peripartum cardiomyopathy. 61
31587432 2020
18
Peripartum Cardiomyopathy Incidence, Risk Factors, Diagnostic Criteria, Pathophysiology, and Treatment Options. 61
32000219 2020
19
A Systematic Review of Diagnosis and Treatment of Acute Limb Ischemia during Pregnancy and Postpartum Period. 61
32442613 2020
20
Human induced pluripotent stem cells for modelling metabolic perturbations and impaired bioenergetics underlying cardiomyopathies. 61
32365198 2020
21
Hypoproteinemia as a parameter of poor perinatal/neonatal outcomes in women with preeclampsia diagnosed as hypertension plus proteinuria. 61
32492636 2020
22
Temporal Changes in Hypertensive Disorders of Pregnancy and Impact on Cardiovascular and Obstetric Outcomes. 61
32273052 2020
23
Outcome in German and South African peripartum cardiomyopathy cohorts associates with medical therapy and fibrosis markers. 61
32064780 2020
24
Characteristics and outcomes of pregnant women with cardiomyopathy stratified by etiologies: A population-based study. 61
31889561 2020
25
Did a shared thioredoxin-reductase gene mutation lead to maternal peripartum cardiomyopathy and fatal dilated cardiomyopathy in her son? A case report. 61
32257832 2020
26
[Peripartum cardiomyopathy: clinical key to diagnosis]. 61
32176218 2020
27
Promoting awareness of peripartum cardiomyopathy (PPCM). 61
32035690 2020
28
Heart Transplantation Outcomes in Adults with Postpartum Cardiomyopathy. 61
32465123 2020
29
Detection and management of arrhythmias in peripartum cardiomyopathy. 61
32420115 2020
30
Extracorporeal membrane oxygenation in pregnancy and the postpartum period: a systematic review of case reports. 61
32439296 2020
31
Pregnancy-associated cardiac dysfunction and the regulatory role of microRNAs. 61
32252821 2020
32
Practice Patterns Surrounding Pregnancy After Heart Transplantation. 61
32237888 2020
33
Left Ventricular Assist Device as Bridge to Recovery - Single Center Experience of Successful Device Explantation. 61
32465435 2020
34
Peripartum cardiomyopathy prognostication using cardiac magnetic resonance imaging. 61
32240001 2020
35
Postpartum psychosis in peripartum cardiomyopathy: a case report. 61
32160870 2020
36
Peripartum cardiomyopathy: basic mechanisms and hope for new therapies. 61
31605117 2020
37
Loperamide toxicity mimicking peripartum cardiomyopathy. 61
31836339 2020
38
Cardiogenic shock complicating peripartum cardiomyopathy: Importance of early left ventricular unloading and bromocriptine therapy. 61
29792513 2020
39
Prognostic nutritional index as a novel marker for prediction of prognosis in patients with peripartum cardiomyopathy. 61
32176104 2020
40
Pulmonary thromboembolism presenting with chest pain in a case of peripartum cardiomyopathy. 61
32180452 2020
41
Comment on: "From labor and delivery to left ventricular assist device: A peripartum cardiomyopathy case report". 61
31735453 2020
42
Complement-Mediated Disorders in Pregnancy. 61
32553248 2020
43
Predictors of early and delayed recovery in peripartum cardiomyopathy: a prospective study of 52 Patients. 61
29945487 2020
44
Deficiency of Cardiac Natriuretic Peptide Signaling Promotes Peripartum Cardiomyopathy-Like Remodeling in the Mouse Heart. 61
31665900 2020
45
Incidence, clinical characteristics, and risk factors of peripartum cardiomyopathy in Nigeria: results from the PEACE Registry. 61
31990449 2020
46
Long-term discontinuation of warfarin in a patient with HeartMate 3 left ventricular assist device without complication. 61
31730719 2020
47
[Peripartum cardimyopathy - risk of delayed diagnosis]. 61
31990362 2020
48
Cardio-obstetrics: Recognizing and managing cardiovascular complications of pregnancy. 61
31990654 2020
49
Left ventricular function recovery in peripartum cardiomyopathy: a cardiovascular magnetic resonance study by myocardial T1 and T2 mapping. 61
31902370 2020
50
Extracorporeal Membrane Oxygenation as Salvage Therapy in the Peripartum Period: A Case Series. 61
31977351 2020

Variations for Peripartum Cardiomyopathy

Expression for Peripartum Cardiomyopathy

Search GEO for disease gene expression data for Peripartum Cardiomyopathy.

Pathways for Peripartum Cardiomyopathy

Pathways related to Peripartum Cardiomyopathy according to GeneCards Suite gene sharing:

(show all 12)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.78 VEGFA SCN5A NRAS GNB3 DRD2 ADRB1
2
Show member pathways
12.68 VEGFA PRL PGF NRAS GNB3 FLT1
3
Show member pathways
12.28 VEGFA PGF NRAS GNB3 FLT1 DRD2
4
Show member pathways
12.18 VEGFA PGF NRAS FLT1
5 12.07 VEGFA NRAS MIR21 MIR10A
6
Show member pathways
11.97 TTN MYH7 ADRB1 ACE
7 11.83 VEGFA SCN5A MIR210 GNB3
8 11.66 VEGFA NRAS MIR210 MIR21 MIR195 MIR146A
9
Show member pathways
11.63 VEGFA PGF FLT1
10 11.6 NRAS DRD2 ADRB1
11 11.07 VEGFA NRAS FLT1
12
Show member pathways
10.34 VEGFA PGF FLT1

GO Terms for Peripartum Cardiomyopathy

Cellular components related to Peripartum Cardiomyopathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.28 VEGFA PRL PGF MIR210 MIR21 MIR146A

Biological processes related to Peripartum Cardiomyopathy according to GeneCards Suite gene sharing:

(show all 27)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.22 VEGFA PRL PGF NRAS GNB3 DRD2
2 gene silencing by miRNA GO:0035195 10.01 MIR210 MIR21 MIR195 MIR146A MIR10A
3 positive regulation of cell proliferation GO:0008284 10 VEGFA PRL PGF MIR21 FLT1
4 negative regulation of gene expression GO:0010629 9.93 VEGFA MIR21 MIR146A ACE
5 miRNA mediated inhibition of translation GO:0035278 9.8 MIR210 MIR21 MIR146A
6 positive regulation of endothelial cell proliferation GO:0001938 9.75 VEGFA PGF NRAS
7 vascular endothelial growth factor receptor signaling pathway GO:0048010 9.73 VEGFA PGF FLT1
8 negative regulation of angiogenesis GO:0016525 9.73 PRL MIR21 MIR146A MIR10A
9 positive regulation of cell migration GO:0030335 9.72 VEGFA MIR210 MIR21 FLT1 CD274
10 cardiac muscle contraction GO:0060048 9.7 TTN SCN5A MYH7
11 negative regulation of endothelial cell proliferation GO:0001937 9.67 PRL MIR21 MIR146A
12 positive regulation of cell migration involved in sprouting angiogenesis GO:0090050 9.65 VEGFA MIR146A MIR10A
13 induction of positive chemotaxis GO:0050930 9.62 VEGFA PGF
14 cardiac muscle fiber development GO:0048739 9.6 VEGFA TTN
15 tube formation GO:0035148 9.59 VEGFA MIR210
16 cardiac muscle hypertrophy GO:0003300 9.58 TTN MIR195
17 sprouting angiogenesis GO:0002040 9.58 VEGFA PGF FLT1
18 hyaloid vascular plexus regression GO:1990384 9.57 FLT1 DRD2
19 negative regulation of vascular associated smooth muscle cell apoptotic process GO:1905460 9.55 MIR210 MIR21
20 positive regulation of mast cell chemotaxis GO:0060754 9.54 VEGFA PGF
21 regulation of heart rate GO:0002027 9.54 SCN5A MYH7 DRD2
22 positive regulation of peptidyl-tyrosine autophosphorylation GO:1900086 9.51 VEGFA ACE
23 regulation of locomotion involved in locomotory behavior GO:0090325 9.46 GNB3 DRD2
24 positive regulation of vascular endothelial growth factor receptor signaling pathway GO:0030949 9.43 VEGFA MIR10A FLT1
25 positive regulation of angiogenesis GO:0045766 9.35 VEGFA PGF MIR210 MIR21 FLT1
26 vascular endothelial growth factor signaling pathway GO:0038084 9.33 VEGFA PGF FLT1
27 positive regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesis GO:1903589 8.92 VEGFA MIR21 MIR146A MIR10A

Molecular functions related to Peripartum Cardiomyopathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.02 MIR210 MIR21 MIR195 MIR146A MIR10A
2 vascular endothelial growth factor receptor binding GO:0005172 8.96 VEGFA PGF

Sources for Peripartum Cardiomyopathy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....